Company’s 36-month beta value is 0.23.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for TMCI is 45.88M, and currently, short sellers hold a 8.90% ratio of that floaft. The average trading volume of TMCI on September 18, 2024 was 814.73K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TMCI) stock’s latest price update
Treace Medical Concepts Inc (NASDAQ: TMCI)’s stock price has increased by 8.45 compared to its previous closing price of 5.21. However, the company has seen a 9.28% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-11 that PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2024 in Vancouver, British Columbia, Canada from September 11-14, 2024.
TMCI’s Market Performance
Treace Medical Concepts Inc (TMCI) has seen a 9.28% rise in stock performance for the week, with a -11.44% decline in the past month and a -6.30% plunge in the past quarter. The volatility ratio for the week is 6.33%, and the volatility levels for the past 30 days are at 5.47% for TMCI. The simple moving average for the last 20 days is -1.46% for TMCI stock, with a simple moving average of -40.65% for the last 200 days.
Analysts’ Opinion of TMCI
Many brokerage firms have already submitted their reports for TMCI stocks, with UBS repeating the rating for TMCI by listing it as a “Neutral.” The predicted price for TMCI in the upcoming period, according to UBS is $6.50 based on the research report published on May 16, 2024 of the current year 2024.
Truist, on the other hand, stated in their research note that they expect to see TMCI reach a price target of $7, previously predicting the price at $17. The rating they have provided for TMCI stocks is “Hold” according to the report published on May 08th, 2024.
Stifel gave a rating of “Hold” to TMCI, setting the target price at $6 in the report published on May 08th of the current year.
TMCI Trading at -13.87% from the 50-Day Moving Average
After a stumble in the market that brought TMCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.64% of loss for the given period.
Volatility was left at 5.47%, however, over the last 30 days, the volatility rate increased by 6.33%, as shares sank -11.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.69% lower at present.
During the last 5 trading sessions, TMCI rose by +7.47%, which changed the moving average for the period of 200-days by -36.58% in comparison to the 20-day moving average, which settled at $5.70. In addition, Treace Medical Concepts Inc saw -55.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMCI starting from Treace John T., who purchase 50,000 shares at the price of $5.31 back on Sep 16 ’24. After this action, Treace John T. now owns 6,523,095 shares of Treace Medical Concepts Inc, valued at $265,630 using the latest closing price.
TREACE JAMES T, the Director of Treace Medical Concepts Inc, purchase 84,000 shares at $5.96 during a trade that took place back on Aug 15 ’24, which means that TREACE JAMES T is holding 1,223,441 shares at $501,035 based on the most recent closing price.
Stock Fundamentals for TMCI
Current profitability levels for the company are sitting at:
- -0.33 for the present operating margin
- 0.81 for the gross margin
The net margin for Treace Medical Concepts Inc stands at -0.32. The total capital return value is set at -0.36. Equity return is now at value -48.60, with -26.77 for asset returns.
Based on Treace Medical Concepts Inc (TMCI), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.56. The debt to equity ratio resting at 0.48. The interest coverage ratio of the stock is -24.63.
Currently, EBITDA for the company is -46.08 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.04. The receivables turnover for the company is 7.77for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.86.
Conclusion
In a nutshell, Treace Medical Concepts Inc (TMCI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
